Loading…
Loading…
EQUITY / NASDAQ · XNCM
PharmaCyte Biotech, Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →05/01/2026 – 07/31/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗0.4001 USD
Observed: 10/02/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
10/02/2026 · 0.4001 USD · Volume 44,653
64 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
05/01/2026 – 07/31/2026 · Units
| Metric | 2027 / Quarter 1 | 2026 / Quarter 1 | Change |
|---|---|---|---|
| Revenue | 0 USD | 0 USD | — |
| Operating profit | -1,006,708 USD | -848,305 USD | — |
| Net income | -5,081,191 USD | -8,360,096 USD | — |
| Operating cash flow | -780,894 USD | -1,993,981 USD | — |
| Cash and cash equivalents | 17,738,991 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2027 / Quarter 105/01/2026 – 07/31/2026ConsolidatedUnits · USD | 2026 / Quarter 104/30/2026 – 04/30/2026ConsolidatedUnits · USD | 2026 / Year end05/01/2025 – 04/30/2026ConsolidatedUnits · USD | 2026 / Quarter 311/01/2025 – 01/31/2026ConsolidatedUnits · USD | 2026 / Quarter 305/01/2025 – 01/31/2026ConsolidatedUnits · USD | 2026 / Quarter 308/01/2025 – 10/31/2025ConsolidatedUnits · USD | 2026 / Quarter 205/01/2025 – 10/31/2025ConsolidatedUnits · USD | 2026 / Quarter 105/01/2025 – 07/31/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 17,738,991 USD | 18,603,899 USD | 18,603,899 USD | 20,165,535 USD | — | — | — | — |
| Financing cash flowCash flow statement | -83,399 USD | — | 6,581,577 USD | — | 6,751,395 USD | — | 6,207,616 USD | 0 USD |
| Net incomeIncome statement | -5,081,191 USD | — | -19,424,654 USD | 746,860 USD | -15,031,211 USD | -7,417,975 USD | -15,778,071 USD | -8,360,096 USD |
| Operating cash flowCash flow statement | -780,894 USD | — | -5,152,914 USD | — | -3,760,352 USD | — | -2,973,504 USD | -1,993,981 USD |
| Operating profitIncome statement | -1,006,708 USD | — | -6,853,713 USD | -2,118,102 USD | -4,342,458 USD | — | -2,224,356 USD | -848,305 USD |
| RevenueIncome statement | 0 USD | — | 0 USD | 0 USD | 0 USD | — | 0 USD | 0 USD |
| Total assetsBalance sheet | 36,712,295 USD | 46,753,242 USD | 46,753,242 USD | 55,873,565 USD | — | — | — | — |
| Total equityBalance sheet | 27,508,504 USD | 33,294,926 USD | 33,294,926 USD | 38,113,013 USD | — | 35,235,089 USD | — | 43,591,588 USD |
| Total liabilitiesBalance sheet | 6,896,682 USD | 11,772,424 USD | 11,772,424 USD | 16,471,229 USD | — | — | — | — |
| Investing cash flowCash flow statement | — | — | 2,000,000 USD | — | 2,000,000 USD | — | -3,000,000 USD | — |
| Report source | Open report ↗ Published: 09/14/2026 | Open report ↗ Published: 09/14/2026 | Open report ↗ Published: 07/29/2026 | Open report ↗ Published: 03/17/2026 | Open report ↗ Published: 03/17/2026 | Open report ↗ Published: 03/17/2026 | Open report ↗ Published: 12/18/2025 | Open report ↗ Published: 09/14/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.